CompletedPhase 1ACTRN12605000520639
A Pharmacokinetic Phase I Study to Assess the Effect of Different Application Sites and Formulations, on the Relative Bioavailability and Pharmacokinetics of Estradiol in postmenopausal women from a Metered Dose Transdermal System (MDTS) as hormone replacement therapy.
Sponsor
FemPharm Pty Ltd and/or Acrux DDS Pty Ltd
Enrollment
12 participants
Start Date
Jul 15, 2002
Study Type
Interventional
Conditions
Eligibility
Min Age: -2147483648 YearsMax Age: -2147483648 Years
Inclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Estradiol MDTS, 7-days, 3-period crossover
Estradiol MDTS, 7-days, 3-period crossover
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000520639